SNPs in LncRNA genes are associated with non‐small cell lung cancer in a Chinese population

Wang, Ruoyang; Feng, Na; Wang, Yu; Gao, Sumeng; Zhang, Fangfang; Qian, Ying; Gao, Ming; Yu, Herbert; Zhou, Baosen; Qian, Biyun

doi:10.1002/jcla.22858

Cited by 10 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these studies display downregulated expressions of circ‐SMARCA5 in some cancers, the involvement of circ‐SMARCA5 in lung cancer has not been clearly clarified, and only one study shows that circ‐SMARCA5 is downregulated in NSCLC tissues compared to the adjacent normal tissues, and it inhibits cell proliferation, migration as well as invasion in NSCLC cell lines . Some recent studies have implied that non‐coding RNAs, especially circRNAs, play crucial roles in pathology and progression of NSCLC . For example, long non‐coding RNA KDM5B anti‐sense RNA 1 enhances tumor progression in NSCLC; circular RNA F‐circSR derived from SLC34A2‐ROS1 fusion gene enhances cell migration in NSCLC; overexpression of circular RNA FARSA promotes NSCLC cell migration and invasion .…”

Section: Discussionmentioning

confidence: 99%

Circular RNA SMARCA5 may serve as a tumor suppressor in non‐small cell lung cancer

Tong

2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractBackground: This study aimed to investigate the correlation of circular RNA SMARCA5 (circ-SMARCA5) expression with clinicopathological characteristics and survival profiles, furthermore, to explore the function of circ-SMARCA5 on regulating cell proliferation and chemotherapy sensitivity in non-small cell lung cancer (NSCLC). Methods:A total of 460 NSCLC patients were retrospectively reviewed, and circ-SMARCA5 expressions in tumor tissue and adjacent tissue were detected by RT-qPCR. Clinical characteristics were collected. Disease-free survival (DFS) and overall survival (OS) were calculated. In vitro, circ-SMARCA5 overexpression and control overexpression plasmids were transfected into NCI-H1437 as well as NCI-H1299 cells, which were further treated with different concentrations of cisplatin and gemcitabine.Results: Circ-SMARCA5 expression was decreased in tumor tissues compared to adjacent tissues. Moreover, circ-SMARCA5 expression negatively correlated with tumor size, lymph node metastasis, and TNM stage, but positively correlated with DFS and OS. Subsequent analysis displayed that circ-SMARCA5 high expression independently predicted prolonged DFS and OS. In vitro, circ-SMARCA5 expression was reduced in NSCLC cell lines (NCI-H650, NCI-H1299, NCI-H1437, and A549) compared to human normal lung bronchus epithelial cell line (BEAS-2B). In NCI-H1437 and NCI-H1299 cells, cell proliferation was decreased by circ-SMARCA5 overexpression, furthermore, chemosensitivity to cisplatin and gemcitabine were enhanced in circ-SMARCA5 overexpression treated cells compared to the control cells. Conclusion:Circ-SMARCA5 may serve as a tumor suppressor in NSCLC, which provides insight to the exploration of novel strategies in NSCLC management. K E Y W O R D Scell proliferation, chemotherapy sensitivity, circular RNA SMARCA5, non-small cell lung cancer, survival

show abstract

Section: Discussionmentioning

confidence: 99%

Circular RNA SMARCA5 may serve as a tumor suppressor in non‐small cell lung cancer

Tong

2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…37,38 A pan-cancer analysis revealed that LINC01614 could be used as diagnostic/prognostic biomarkers for digestive systems, respiratory systems, head and neck cancers, and so forth. 39 Liu et al's 40 study revealed that rs3113503 in LINC01614 was significantly associated with the non-small cell lung cancer risk. However, to date, little research has been conducted on the association between the functional variants of LINC01614 and HNSCC risk, let alone the underlying mechanisms.…”

mentioning

confidence: 99%

Risk SNP‐mediated LINC01614 upregulation drives head and neck squamous cell carcinoma progression via PI3K/AKT signaling pathway

Hou

Zhou

et al. 2022

Molecular Carcinogenesis

View full text Add to dashboard Cite

As potential biomarkers and therapeutic targets, long noncoding RNAs (lncRNAs) are involved in the tumorigenesis of various tumors. Genetic variation in long noncoding regions can lead to lncRNA dysfunction and even cancer. Nevertheless, studies on the association between lncRNA‐associated single‐nucleotide polymorphisms (SNPs) and the risk of head and neck squamous cell carcinoma (HNSCC) remain inadequate. Here, we aimed to explore the association between SNPs in LINC01614 and HNSCC risk, and the potential role of LINC01614 in tumorigenesis. In this study, we found that rs16854802 A > G (odds ratio [OR] = 1.42, 95% confidence interval [CI]: 1.22–1.77, p < 0.001) and rs3113503 G > C (OR = 1.38, 95% CI: 1.15–1.64, p < 0.001) in LINC01614 increased the risk of HNSCC in the Chinese population. Functional bioinformatic analysis and luciferase reporter assay revealed that rs3113503 G > C variant disrupted the binding of miRNA‐616‐3p to LINC01614, which resulted in the increased expression of LINC01614. Further analysis of the TCGA database demonstrated that the upregulated LINC01614 in HNSCC cancer tissues was associated with poor prognostic in HNSCC patients. In vitro experiments showed that knockdown of LINC01614 inhibited the proliferation, invasion, and migration ability of HNSCC cells. Mechanistically, allele C of rs3113503 in LINC01614 was more effective than allele G in activating the PI3K/AKT signaling pathway. Moreover, the reduced expression of LINC01614 also inhibited the activation of the PI3K/AKT signaling pathway. In summary, our findings revealed that the risk SNP rs3113503 G > C in LINC01614 altered the binding to miR‐616‐3p, which led to increased LINC01614 expression and promoted HNSCC progression by activating the PI3K/AKT signaling pathway.

show abstract

“…Furthermore, SNPs can also affect functionality of long non-coding RNAs (lncRNAs), another group of regulatory RNAs that participate in chromatin modifications, transcription, and post-transcriptional processing. Notably, to date, 495,729 SNPs have been identified in human lncRNAs transcripts [175], with many of these mutations shown to affect lncRNA structure [176] or their interactions with miRNA [175,177,178]. The SNP-related impairment of lncRNA function is sometimes associated with human diseases including carcinogenesis and responses to chemotherapy [179][180][181][182].…”

Section: Snpsmentioning

confidence: 99%

The Effects of Single Nucleotide Polymorphisms in Cancer RNAi Therapies

Gebert

Jaśkiewicz

Moszyńska

et al. 2020

Cancers

View full text Add to dashboard Cite

Tremendous progress in RNAi delivery methods and design has allowed for the effective development of siRNA-based therapeutics that are currently under clinical investigation for various cancer treatments. This approach has the potential to revolutionize cancer therapy by providing the ability to specifically downregulate or upregulate the mRNA of any protein of interest. This exquisite specificity, unfortunately, also has a downside. Genetic variations in the human population are common because of the presence of single nucleotide polymorphisms (SNPs). SNPs lead to synonymous and non-synonymous changes and they occur once in every 300 base pairs in both coding and non-coding regions in the human genome. Much less common are the somatic mosaicism variations associated with genetically distinct populations of cells within an individual that is derived from postzygotic mutations. These heterogeneities in the population can affect the RNAi’s efficacy or more problematically, which can lead to unpredictable and sometimes adverse side effects. From a more positive viewpoint, both SNPs and somatic mosaicisms have also been implicated in human diseases, including cancer, and these specific changes could offer the ability to effectively and, more importantly, selectively target the cancer cells. In this review, we discuss how SNPs in the human population can influence the development and success of novel anticancer RNAi therapies and the importance of why SNPs should be carefully considered.

show abstract

SNPs in LncRNA genes are associated with non‐small cell lung cancer in a Chinese population

Cited by 10 publications

References 33 publications

Circular RNA SMARCA5 may serve as a tumor suppressor in non‐small cell lung cancer

Circular RNA SMARCA5 may serve as a tumor suppressor in non‐small cell lung cancer

Risk SNP‐mediated LINC01614 upregulation drives head and neck squamous cell carcinoma progression via PI3K/AKT signaling pathway

The Effects of Single Nucleotide Polymorphisms in Cancer RNAi Therapies

Contact Info

Product

Resources

About